



NEONATAL Medication Monograph

# AMOXICILLIN + CLAVULANIC ACID (Oral)





This document should be read in conjunction with this [DISCLAIMER](#)

**Unrestricted:** Any prescriber may initiate treatment

**⚠ Dosing Schedule below is for Curam Duo 400/57 (80mg/mL) ® Formulation.**  
**Not all products are interchangeable, contact Pharmacy for further information.**

<b>Presentation</b>	Powder for oral suspension Curam Duo 400/57® Amoxicillin 80 mg/mL, clavulanic acid 11.4 mg/mL (Ratio 7:1)
<b>Description</b>	Broad spectrum penicillin antibiotic in combination with a β-lactamase inhibitor.
<b>Indications</b>	For treatment of bacterial infections caused by sensitive organisms
<b>Contraindication</b>	Hypersensitivity to a penicillin History of cholestatic jaundice or hepatic dysfunction associated with amoxicillin with clavulanic acid.
<b>Precaution</b>	<ul style="list-style-type: none"> <li>• Renal impairment</li> <li>• Hepatic dysfunction</li> <li>• Cholestatic jaundice – rarely reported in children.</li> <li>• Oral suspension - contains aspartame; use with caution in patients with phenylketonuria</li> </ul>
<b>Dose</b>	<p><b>Oral:</b> <i>Dosing is based on amoxicillin content</i> <i>Curam Duo® amoxicillin Concentration = 80mg/mL</i></p> <p>15 - 22.5mg/ kg/ dose every 12 hours</p>
<b>Dose Adjustment</b>	Dose adjustment required in renal impairment
<b>Adverse Reactions</b>	<b>Common:</b> diarrhoea, vomiting, oral candidiasis
	<b>Serious:</b> urticaria, anaemia, phlebitis, cholestatic jaundice, thrombocytopenia purpura, CNS toxicity with high doses or severe renal impairment

<b>Preparation</b>	<p><b>Oral:</b></p> <p><b>Reconstitution</b> Tap bottle until all the powder flows freely. Measure 55mL of Water for Irrigation Add approximately half of the total water and shake vigorously, add remainder of the water and again shake vigorously until suspended.</p> <p>Final Concentration of amoxicillin content is 400mg/5mL = <b>80mg/mL</b></p>
<b>Administration</b>	<p>Shake well before use</p> <p>Administer at the start of a feed to decrease the frequency or severity of GI side effects</p>
<b>Monitoring</b>	<p>Renal, hepatic function and FBC if on prolonged therapy</p>
<b>Storage</b>	<p>Store dry powder at room temperature, below 25°C</p> <p>Store reconstituted oral suspension in refrigerator. Discard 7 days after reconstitution</p>
<b>Notes</b>	<p>There is minimal published evidence about using amoxicillin with clavulanic acid in neonates</p> <p>Products are not interchangeable</p>
<b>Related clinical guidelines</b>	<p>WNHS Policy: <a href="#">Antimicrobial Stewardship</a></p>
<b>References</b>	<p>Takemoto CK, Hodding JH, Kraus DM. Pediatric &amp; neonatal dosage handbook with international trade names index : a universal resource for clinicians treating pediatric and neonatal patients. 24th ed. Hudson (Ohio): Lexicomp; 2019</p> <p>Australian Medicines Handbook. Amoxicillin with Clavulanate. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia); 2020 [cited 2020 Sept 04]. Available from: <a href="https://amhonline.amh.net.au/">https://amhonline.amh.net.au/</a></p> <p>British National Formulary. BNF for Children. 2018-19 ed. London, UK: BMJ Group and Pharmaceutical Press; 2019</p> <p>Huttner A, Bielicki J, Clements MN, et al. Oral amoxicillin and amoxicillin-clavulanic acid: properties, indications and usage. <i>Clin Microbiol Infect.</i> 2020;26(7):871-879. doi:10.1016/j.cmi.2019.11.028</p>

Keywords	Amox/clav, Co-amoxiclav, curam duo, amoxicillin, infection		
Publishing:	<input checked="" type="checkbox"/> Intranet <input checked="" type="checkbox"/> Internet		
Document owner:	Head of Department - Neonatology		
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate		
Date first issued:	August 2008	Version:	3.0
Last reviewed:	September 2020	Next review date:	September 2023
Endorsed by:	Neonatal Directorate Management Group	Date:	September 2020
Standards Applicable:	NSQHS Standards: 1  Governance, 3  Infection Control, 4  Medication Safety, 8  Acute Deterioration		
<p><b>Printed or personally saved electronic copies of this document are considered uncontrolled.</b></p> <p><b>Access the current version from the WNHS website.</b></p> <p><b>For any enquiries relating to this guideline, please email <a href="mailto:KEMH.PharmacyAdmin@health.wa.gov.au">KEMH.PharmacyAdmin@health.wa.gov.au</a></b></p>			

© Department of Health Western Australia 2019